A novel missense mutation responsible for factor VII deficiency in research Beagle colonies

被引:43
作者
Callan, M. B.
Aljamali, M. N.
Margaritis, P.
Griot-Wenk, M. E.
Pollak, E. S.
Werner, P.
Giger, U.
High, K. A.
机构
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA
[3] Univ Bern, Bern, Switzerland
[4] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[5] Howard Hughes Med Inst, Philadelphia, PA USA
关键词
Beagles; factor VII deficiency; missense mutation; COAGULATION-FACTOR-VII; ACTIVATED FACTOR-VII; FACTOR-LIKE DOMAIN; TISSUE FACTOR; THROMBIN; PLASMA; DOG;
D O I
10.1111/j.1538-7836.2006.02203.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Canine factor VII (cFVII) deficiency, an autosomal recessive trait originally identified in research Beagles, is associated with a mild to moderate bleeding tendency. Objective: Our aim was to identify and characterize the mutation causing cFVII deficiency. Methods: In order to sequence the coding regions of the cFVII gene, we cloned the cFVII cDNA. Genomic DNA and plasma from FVII-deficient Beagles and obligate carriers were utilized. Results: In all FVII-deficient dogs, we identified a single causative G to A missense mutation in exon 5, encoding the second epidermal growth factor-like domain, resulting in substitution of glycine 96 by glutamic acid, with plasma FVII coagulant activity of <= 4% in affected Beagles. In vitro expression indicated that the majority (96%) of cFVII-G96E protein was retained intracellularly. In addition, analysis of purified recombinant wild-type and mutant cFVII proteins demonstrated reduced activity of the mutant (< 2%) compared with wild-type. Rotational thromboelastometry revealed a severe impairment of clotting activity in affected Beagles, and heterozygotes also exhibited changes in coagulation-based assays. Using a mutation-specific polymerase chain reaction/restriction digest that allows rapid identification of the G96E mutation, we surveyed a US research Beagle colony and identified a mutant allelic frequency of 31%. Conclusions: We have identified a single causative mutation for cFVII deficiency that may have implications for pharmacotoxicologic research, because reduced FVII coagulant activity may alter hemostatic and/or cardiovascular endpoints in this commonly used animal species.
引用
收藏
页码:2616 / 2622
页数:7
相关论文
共 22 条
[1]   Chromosome-specific single-locus FISH probes allow anchorage of an 1800-marker integrated radiation-hybrid/linkage map of the domestic dog genome to all chromosomes [J].
Breen, M ;
Jouquand, S ;
Renier, C ;
Mellersh, CS ;
Hitte, C ;
Holmes, NG ;
Chéron, A ;
Suter, N ;
Vignaux, F ;
Bristow, AE ;
Priat, C ;
McCann, E ;
André, C ;
Boundy, S ;
Gitsham, P ;
Thomas, R ;
Bridge, WL ;
Spriggs, HF ;
Ryder, EJ ;
Curson, A ;
Sampson, J ;
Ostrander, EA ;
Binns, MM ;
Galibert, F .
GENOME RESEARCH, 2001, 11 (10) :1784-1795
[2]  
CAPEL-EDWARDS K, 1968, Laboratory Animals (London), V2, P105, DOI 10.1258/002367768781082942
[3]   Analysis of the genotypes and phenotypes of 37 unrelated patients with inherited factor VII deficiency [J].
Giansily-Blaizot, M ;
Aguilar-Martinez, P ;
Biron-Andreani, C ;
Janjean, P ;
Igual, H ;
Schved, JF .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2001, 9 (02) :105-112
[4]   Two novel mutations in severe factor VII deficiency [J].
Gomez, K ;
Laffan, MA ;
Kemball-Cook, G ;
Pasi, J ;
Layton, M ;
Singer, JD ;
Tuddenham, EGD ;
McVey, JH .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (01) :105-110
[5]   Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII [J].
Hunault, M ;
Arbini, AA ;
Carew, JA ;
Peyvandi, F ;
Bauer, KA .
BLOOD, 1999, 93 (04) :1237-1244
[6]   Characterization of a factor VII molecule carrying a mutation in the second epidermal growth factor-like domain [J].
Kavlie, A ;
Örning, L ;
Grindflek, A ;
Stormorken, H ;
Prydz, H .
THROMBOSIS AND HAEMOSTASIS, 1998, 79 (06) :1136-1143
[7]   Coagulation factor VII Gln100→Arg -: Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function [J].
Kemball-Cook, G ;
Johnson, DJD ;
Takamiya, O ;
Banner, DW ;
McVey, JH ;
Tuddenham, EGD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (14) :8516-8521
[8]  
Macpherson R, 1999, CAN VET J, V40, P503
[9]   Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated factor VII [J].
Margaritis, P ;
Arruda, VR ;
Aljamali, M ;
Camire, RM ;
Schlachterman, A ;
High, KA .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (07) :1025-1031
[10]  
McVey JH, 2001, HUM MUTAT, V17, P3, DOI 10.1002/1098-1004(2001)17:1<3::AID-HUMU2>3.0.CO